Ulcerative colitis treatment recommended by NICE

Vedolizumab (Entyvio) has been accepted by NICE for treating adults with moderately to severely active ulcerative colitis.

The recommended dosage for treating ulcerative colitis is 300mg of vedolizumab given by intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter. | SCIENCE PHOTO LIBRARY
The recommended dosage for treating ulcerative colitis is 300mg of vedolizumab given by intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter. | SCIENCE PHOTO LIBRARY

Entyvio is indicated for patients who have had an inadequate response to, lost response to, or are intolerant of, either conventional therapy or a tumour necrosis factor antagonist.

The recommendation by NICE states that vedolizumab should be discontinued if it stops working or surgery is required.

An assessment should take place every 12 months to determine whether treatment should be continued. Patients who are in complete remission at 12 months can stop treatment and restart later if symptoms return.

Approval for NHS use was granted on the condition that the company provides vedolizumab with the discount agreed in the patient access scheme.

Further information
NICE technology appraisal TA342

Vedolizumab is a humanised monoclonal antibody that acts specifically in the gut. It targets α4β7 integrin, which is responsible for the recruitment of white blood cells to inflamed bowel tissue.

The most common adverse effects of vedolizumab are nasopharyngitis, headache and joint pain.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more